Investors Buy Large Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) was the target of unusually large options trading on Wednesday. Investors bought 1,002 put options on the company. This is an increase of 1,791% compared to the average daily volume of 53 put options.

Insider Buying and Selling

In other news, insider Carl Hull acquired 175,000 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was purchased at an average price of $5.64 per share, for a total transaction of $987,000.00. Following the completion of the acquisition, the insider now owns 175,000 shares in the company, valued at $987,000. This trade represents a ? increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.63% of the stock is owned by insiders.

Institutional Investors Weigh In On Maravai LifeSciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in MRVI. GAMMA Investing LLC raised its holdings in Maravai LifeSciences by 310.2% during the second quarter. GAMMA Investing LLC now owns 3,585 shares of the company’s stock worth $26,000 after acquiring an additional 2,711 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Maravai LifeSciences during the 2nd quarter worth approximately $32,000. Blue Trust Inc. bought a new stake in shares of Maravai LifeSciences during the 2nd quarter worth approximately $44,000. Venturi Wealth Management LLC acquired a new stake in shares of Maravai LifeSciences in the 3rd quarter valued at approximately $47,000. Finally, Custom Index Systems LLC bought a new position in shares of Maravai LifeSciences in the third quarter valued at $97,000. 50.25% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on MRVI shares. Royal Bank of Canada decreased their price target on shares of Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating for the company in a report on Friday, November 8th. Morgan Stanley downgraded Maravai LifeSciences from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $11.00 to $10.00 in a report on Tuesday, August 13th. William Blair reiterated a “market perform” rating on shares of Maravai LifeSciences in a report on Friday, November 8th. Wells Fargo & Company started coverage on Maravai LifeSciences in a research note on Tuesday, August 27th. They set an “overweight” rating and a $10.00 target price for the company. Finally, UBS Group lifted their price target on shares of Maravai LifeSciences from $8.50 to $11.00 and gave the company a “neutral” rating in a research note on Thursday, August 8th. Five research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $10.33.

Maravai LifeSciences Stock Performance

Shares of MRVI stock opened at $5.92 on Friday. Maravai LifeSciences has a 12 month low of $4.28 and a 12 month high of $11.56. The company’s fifty day simple moving average is $7.16 and its 200-day simple moving average is $8.19. The firm has a market cap of $1.49 billion, a PE ratio of -3.61 and a beta of 0.02. The company has a quick ratio of 9.94, a current ratio of 10.74 and a debt-to-equity ratio of 0.89.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.